Kaken与强生签订Stat6全球许可协议

界面
26 Dec 2024

日本制药公司Kaken于12月26日宣布,与强生公司就Kaken正在开发的STAT6项目的全球开发、生产和商业化签署了一份许可协议。根据协议条款,Kaken将向强生公司授予STAT6项目全球开发、生产和商业化的独家许可,包括KP-723(一种处于临床前开发阶段的口服STAT6抑制剂)。Kaken将推进KP-723完成I期临床试验,之后强生将在全球范围内进行临床开发和商业化。Kaken将保留在日本的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10